People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Other, Software / Tech, Biotech, Biotechnology, Pharma, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Freenome Holdings, Inc. | — | Other | Series D+ | $750.6M | $3.4B | 2017 |
| Apeel Technology, Inc. | — | Software / Tech | Series D+ | $534.6M | $6.1B | 2016 |
| Nautilus Biotechnology, Inc. | — | Biotech | Series D+ | $303.3M | $6.0B | 2018 |
| Genesis Therapeutics, Inc. | — | Biotechnology | Series D+ | $297.4M | $3.3B | 2023 |
| BioAge Labs, Inc. | — | Biotechnology | Series D+ | $194.4M | $2.4B | 2024 |
| Insitro, Inc. | — | Biotechnology | Series D+ | $143.2M | $5.9B | 2020 |
| Nobell Foods, Inc. | — | Biotechnology | Series C | $102.4M | $2.1B | 2019 |
| Scribe Therapeutics, Inc. | — | Pharma | Series D+ | $100.0M | $2.9B | 2021 |
| Asimov Inc. | — | Other Technology | Series A | $4.7M | $130.4M | 2017 |
Vijay Pande at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Vijay Pande on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Robert Nelsen | 1 | 22 |
| Amir Nashat | 1 | 14 |
| Walter Robb | 1 | 11 |
| Ira Ehrenpreis | 1 | 10 |
| Patrick Enright | 1 | 10 |
| Stuart Nagae | 1 | 9 |
| Yves Sisteron | 1 | 8 |
| Peter Kolchinsky | 1 | 8 |
| James Healy | 1 | 8 |
| Jason Spievak | 1 | 7 |
| JAMES ROGERS | 1 | 7 |
| Dov Goldstein | 1 | 6 |
| Kyle Vogt | 1 | 5 |
| Chris Rivest | 1 | 5 |
| Randal Scott | 1 | 4 |
| Charles Roberts | 1 | 4 |
| Matthew Posard | 1 | 4 |
| William McCarthy | 1 | 4 |
| MATTHEW S. MCILWAIN | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.